Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Harmony Biosciences Holdings (HRMY) Other Operating Expenses (2019 - 2025)

Harmony Biosciences Holdings (HRMY) has disclosed Other Operating Expenses for 7 consecutive years, with $29.2 million as the latest value for Q4 2025.

  • Quarterly Other Operating Expenses rose 5.72% to $29.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $154.7 million through Dec 2025, up 39.45% year-over-year, with the annual reading at $119.5 million for FY2025, 7.75% up from the prior year.
  • Other Operating Expenses hit $29.2 million in Q4 2025 for Harmony Biosciences Holdings, down from $29.5 million in the prior quarter.
  • In the past five years, Other Operating Expenses ranged from a high of $65.2 million in Q2 2025 to a low of $15.5 million in Q1 2021.
  • Historically, Other Operating Expenses has averaged $25.5 million across 5 years, with a median of $24.0 million in 2023.
  • Biggest five-year swings in Other Operating Expenses: grew 2.66% in 2024 and later soared 128.83% in 2025.
  • Year by year, Other Operating Expenses stood at $19.1 million in 2021, then grew by 10.29% to $21.1 million in 2022, then rose by 27.57% to $26.9 million in 2023, then rose by 2.66% to $27.6 million in 2024, then rose by 5.72% to $29.2 million in 2025.
  • Business Quant data shows Other Operating Expenses for HRMY at $29.2 million in Q4 2025, $29.5 million in Q3 2025, and $65.2 million in Q2 2025.